Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy

Journal of Clinical Oncology

Volumn 21, Issue 18, 2003, Pages 3526-3534

  Younes, Anas ^a   Kadin, Marshall E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; CD30 ANTIGEN; CD40 LIGAND; DEATH RECEPTOR 4; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; CD30 LIGAND; CD40 ANTIGEN; LIGAND; MEMBRANE PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TNFSF8 PROTEIN, HUMAN; TRAF3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; CANCER CELL; CANCER THERAPY; CELL STRUCTURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; HUMAN; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD30; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CD30 LIGAND; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 3; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0142026056     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.037     Document Type: Review

References (100)

1. Kwon B, Youn BS, Kwon BS: Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes. Curr Opin Immunol 11:340-345, 1999
2. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104:487-501, 2001
3. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 76:959-962, 1994
4. Screaton G, Xu XN: T cell life and death signalling via TNF-receptor family members. Curr Opin Immunol 12:316-322, 2000
5. Durkop H, Latza U, Hummel M, et al: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68:421-427, 1992
6. Cabanillas F, Armitage J, Pugh WC, et al: Lymphomatoid papulosis: A T-cell dyscrasia with a propensity to transform into malignant lymphoma. Ann Intern Med 122:210-217, 1995
7. Oudejans JJ, Dukers DF, Jiwa NM, et al: Expression of Epstein-Barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV. J Clin Pathol 49:897-902, 1996
8. Falini B, Pileri S, Pizzolo G, et al: CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1-14, 1995
9. Chiarle R, Podda A, Prolla G, et al: CD30 in normal and neoplastic cells. Clin Immunol 90:157-164, 1999
10. de Bruin PC, Gruss HJ, van der Valk P, et al: CD30 expression in normal and neoplastic lymphoid tissue: Biological aspects and clinical implications. Leukemia 9:1620-1627, 1995
11. Younes A, Carbone A: CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 14:135-143, 1999
12. Stein H, Mason DY, Gerdes J, et al: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858, 1985
13. Agnarsson BA, Kadin ME: Ki-1 positive large cell lymphoma: A morphologic and immunologic study of 19 cases. Am J Surg Pathol 12:264-274, 1988
14. Filippa DA, Ladanyi M, Wollner N, et al: CD30 (Ki-1)-positive malignant lymphomas: Clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease. Blood 87:2905-2917, 1996
15. Stein H, Foss HD, Durkop H, et al: CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 96:3681-3695, 2000
16. Gattei V, Degan M, Gloghini A, et al: CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 89:2048-2059, 1997
17. Takeshita M, Akamatsu M, Ohshima K, et al: CD30 (Ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinctive immunohistological and clinical characteristics. Histopathology 26:539-546, 1995
18. Latza U, Foss HD, Durkop H, et al: CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol 146:463-471, 1995
19. Trovato M, Villari D, Ruggeri RM, et al: Expression of CD30 ligand and CD30 receptor in normal thyroid and benign and malignant thyroid nodules. Thyroid 11:621-628, 2001
20. Horn-Lohrens O, Tiemann M, Lange H, et al: Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 60:539-544, 1995
21. Nadali G, Tavecchia L, Zanolin E, et al: Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 91:3011-3016, 1998
22. Pizzolo G, Vinante F, Chilosi M, et al: Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: Relationship with disease activity and clinical stage. Br J Haematol 75:282-284, 1990
23. Pizzolo G, Vinante F, Nadali G, et al: High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 108:251-253, 1997
24. Caligaris-Cappio F, Bertero MT, Converso M, et al: Circulating levels of soluble CD30, a marker of cells producing Th2- type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 13:339-343, 1995
25. Gerli R, Muscat C, Bistoni O, et al: High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 102:547-550, 1995
26. Okumura M, Hidaka Y, Kuroda S, et al: Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 82:1757-1760, 1997
27. Pizzolo G, Romagnani S: CD30 molecule (Ki-1 Ag): More than just a marker of CD30+ lymphoma. Haematologica 80:357-366, 1995
28. Zinzani PL, Pileri S, Bendandi M, et al: Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 16:1532-1537, 1998
29. Gruss HJ, Duyster J, Hermann F: Structural and biological features of the TNF receptor and TNF ligand superfamilies: Interactive signals in the pathobiology of Hodgkin's disease. Ann Oncol 7:19-26, 1996
30. Smith CA, Gruss HJ, Davis T, et al: CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349-1360, 1993
31. Younes A, Consoli U, Zhao S, et al: CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol 93:569-571, 1996
32. Younes A, Consoli U, Snell V, et al: CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol 15:3355-3362, 1997
33. Younes A, Zhao S, Zhang X, et al: CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's disease. Ann Oncol 8:97-100, 1997
34. Pinto A, Aldinucci D, Gloghini A, et al: Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 88:3299-3305, 1996
35. Gruss HJ, Pinto A, Gloghini A, et al: CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol 149:469-481, 1996
36. Molin D, Fischer M, Xiang Z, et al: Mast cells express functional CD30 ligand and are the predominant CD30L- positive cells in Hodgkin's disease. Br J Haematol 114:616-623, 2001
37. Romagnani P, Annunziato F, Manetti R, et al: High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood 91:3323-3332, 1998
38. Clark EA: CD40: A cytokine receptor in search of a ligand. Tissue Antigens 36:33-36, 1990
39. Clark EA, Ledbetter JA: Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A 83:4494-4498, 1986
40. Gordon J, Pound JD: Review article: Fortifying B cells with CD154: An engaging tale of many hues. Immunology 100:269-280, 2000
41. van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 67:2-17, 2000
42. Young LS, Eliopoulos AG, Gallagher NJ, et al: CD40 and epithelial cells: Across the great divide. Immunol Today 19:502-506, 1998
43. Karmann K, Hughes CC, Schechner J, et al: CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A 92:4342-4346, 1995
44. Hollenbaugh D, Mischel-Petty N, Edwards CP, et al: Expression of functional CD40 by vascular endothelial cells. J Exp Med 182:33-40, 1995
45. Sbih-Lammali F, Clausse B, Ardila-Osorio H, et al: Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: Opposite effects of CD95 and CD40 stimulation. Cancer Res 59:924-930, 1999
46. Carbone A, Gloghini A, Gattei V, et al: Expression of functional CD40 antigen on Reed-Stemberg cells and Hodgkin's disease cell lines. Blood 85:780-789, 1995
47. Armitage RJ, Sato TA, Macduff BM, et al: Identification of a source of biologically active CD40 ligand. Eur J Immunol 22:2071-2076, 1992
48. Fanslow WC, Srinivasan S, Paxton R, et al: Structural characteristics of CD40 ligand that determine biological function. Semin Immunol 6:267-278, 1994
49. Graf D, Muller S, Korthauer U, et al: A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 25:1749-1754, 1995
50. Mazzei GJ, Edgerton MD, Losberger C, et al: Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 270:7025-7028, 1995
51. Pietravalle F, Lecoanet-Henchoz S, Blasey H, et al: Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem 271:5965-5967, 1996
52. Lane P, Brocker T, Hubele S, et al: Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med 177:1209-1213, 1993
53. Younes A, Snell V, Consoli U, et al: Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 100:135-141, 1998
54. Viallard JF, Solanilla A, Gauthier B, et al: Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 99:2612-2614, 2002
55. Clodi K, Asgary Z, Zhao S, et al: Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 103:270-275, 1998
56. Kato K, Santana-Sahagan E, Rassenti LZ, et al: The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 104:947-955, 1999
57. Schattner EJ, Mascarenhas J, Reyfman I, et al: Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood 91:2689-2697, 1998
58. Moses AV, Williams SE, Strussenberg JG, et al: HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphomas. Nat Med 3:1242-1249, 1997
59. Trentin L, Zambello R, Sancetta R, et al: B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res 57:4940-4947, 1997
60. Pham LV, Tamayo AT, Yoshimura LC, et al: A CD40 signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity 16:37-50, 2002
61. Anderson DM, Maraskovsky E, Billingsley WL, et al: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179, 1997
62. Hsu H, Lacey DL, Dunstan CR, et al: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96:3540-3545, 1999
63. Li J, Sarosi I, Van XQ, et al: RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 97:1566-1571, 2000
64. Wong BR, Josien R, Choi Y: TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 65:715-724, 1999
65. Wong BR, Josien R, Lee SY, et al: TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186:2075-2080, 1997
66. Bucay N, Sarosi I, Dunstan CR, et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268, 1998
67. Emery JG, McDonnell P, Burke MB, et al: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367, 1998
68. Kong YY, Boyle WJ, Penninger JM: Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol 77:188-193, 1999
69. Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997 (comments)
70. Yun TJ, Chaudhary PM, Shu GL, et al: OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 161:6113-6121, 1998
71. Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
72. Goltzman D: Osteolysis and cancer. J Clin Invest 107:1219-1220, 2001
73. Fiumara P, Snell V, Li Y, et al: Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 98:2784-2790, 2001
74. Zhang J, Dai J, Qi Y, et al: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235-1244, 2001
75. Sezer O, Heider U, Jakob C, et al: Human bone marrow myeloma cells express RANKL. J Clin Oncol 20:353-354, 2002
76. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682, 1995
77. Pitti RM, Marsters SA, Ruppert S, et al: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690, 1996
78. Walczak H, Krammer PH: The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256:58-66, 2000
79. Griffith TS, Lynch DH: TRAIL: A molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10:559-563, 1998
80. Degli-Esposti M: To die or not to die: The quest of the TRAIL receptors. J Leukoc Biol 65:535-542, 1999
81. Ashkenazi A, Dixit VM: Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255-260, 1999
82. Pan G, O'Rourke K, Chinnaiyan AM, et al: The receptor for the cytotoxic ligand TRAIL. Science 276:111-113, 1997
83. Pan GH, Ni J, Wei YF, et al: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818, 1997
84. Sheridan JP, Marsters SA, Pitti RM, et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821, 1997
85. Chaudhary PM, Eby M, Jasmin A, et al: Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7:821-830, 1997
86. Schneider P, Bodmer JL, Thome M, et al: Characterization of two receptors for TRAIL. FEBS Lett 416:329-334, 1997
87. Walczak H, Degli-Esposti MA, Johnson RS, et al: TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J 16:5386-5397, 1997
88. Wu GS, Burns TF, McDonald ER, et al: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17:141-143, 1997
89. Screaton GR, Mongkolsapaya J, Xu XN, et al: TRICK2: A new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 7:693-696, 1997
90. Pan G, Ni J, Yu G, et al: TRUNDD: A new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEES Lett 424:41-45, 1998
91. Degli-Eesposti MA, Dougall WC, Smolak PJ, et al: The novel receptor TRAIL-R4 induces NF-Kappa-B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813-820, 1997
92. Degli-Eesposti MA, Smolak PJ, Walczak H, et al: Cloning and characterization of TRAIL-R3: A novel member of the emerging TRAIL receptor family. J Exp Med 186:1165-1170, 1997
93. Sheikh MS, Huang Y, Fernandez-Salas EA, et al: The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-rcgulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 18:4153-4159, 1999
94. Marsters SA, Sheridan JP, Pitti RM, et al: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7:1003-1006, 1997
95. LeBlanc H, Lawrence D, Varfolomeev E, et al: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8:274-281, 2002
96. Kieff E: Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci U S A 94:12732, 1997
97. Lee SY, Choi Y: TRAF-interacting protein (TRIP): A novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J Exp Med 185:1275-1285, 1997
98. Aizawa S, Nakano H, Ishida T, et al: Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 272:2042-2045, 1997
99. Horie R, Watanabe T, Morishita Y, et al: Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21:2493-2503, 2002
100. Amakawa R, Hakem A, Kundig TM, et al: Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84:551-562, 1996